Mylab Receives Approval for HPV RT-PCR Test to Detect Cervical Cancer


The test has high accuracy and sensitivity and is suitable for mass screening with full automation platforms

Human papillomavirus (HPV) is responsible for more than 95% of cervical cancer. Molecular tests to detect HPV play a crucial role in the prevention of cervical cancer. Continuing its commitment to introducing quality diagnostics, Pune-based start-up Mylab Discovery Solutions has launched the PathoDetect HPV Detection Test, a real-time PCR-based screening solution to detect high-intensity HPV types risk in people.

The regulatory agency-approved PathoDetect HPV Detection Test detects and differentiates the presence of high-risk HPV strains, including 16 and 18, which cause most cervical cancers.

One of the important advantages of this test is that a woman with a positive (High Risk HPV) cervical screening result may be recommended further follow-up tests at more frequent intervals. A negative test for the high-risk HPV genotypes would mean a longer interval between the next screening test.

Mylab also plans to launch an expansion of this kit that can simultaneously detect up to 15 high-risk and distinguishing features of HPV 16 and 18, covering more than 95% of cervical cancer cases.

Commenting on the launch of the PathoDetect HPV Detection Test, Hasmukh Rawal, Co-Founder and CEO of Mylab said, “Cervical cancer is preventable; Therefore, with effective screening, early diagnosis of HPV, and timely intervention by gynecologists, HPV can often be successfully treated.”

The test enables high-throughput testing that is accurate, automated, easy and reliable with Mylab Compact platform series automations within 2 hours without the need for high-end infrastructure or technical expertise.


Comments are closed.